Lenzing stock adds financing to its plant-sale turnaround test

Published on 11/09/2026 at 17:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lenzing stock faces a new financing and plant-sale test as management reshapes the group. A buyer shortlist for Heiligenkreuz is due later this month.

Financing and Plant Sales Shape Turnaround

Lenzing is preparing additional financing while reviewing strategic options for several production sites.
Adjusted profitability improved in the first nine months, but impairments and restructuring costs kept the reported result in the red.
Investors now await progress on Heiligenkreuz, the Indonesian divestment and the 2026 earnings target.

Lenzing, AT0000644505, Illustration mit AI erstellt.

Lenzing is adding a new financing milestone to its restructuring agenda as it works through the future of its European production network. According to ad-hoc-news.de, the company is arranging roughly EUR 300 million in additional financing, with about half already binding. Full implementation is targeted for the end of 2026.

Funding Supports a Wider Restructuring

The planned financing follows a completed capital increase of around EUR 300 million. Together, the measures give Lenzing additional financial capacity while management reshapes its plant network and evaluates asset sales.

At Heiligenkreuz, around 30 potential buyers are under consideration. The field is expected to narrow in mid-November, with a decision on a potential owner due by year-end. Production is scheduled to continue through the end of March 2027 if the site is not transferred earlier.

Lenzing is also reviewing value-optimised sale options for Heiligenkreuz and Grimsby. The sales process for its Indonesian fibre production site remains under way, while Grimsby production is scheduled to stop by the end of 2027.

Margin Progress Meets Restructuring Costs

The first nine months of 2026 showed a mixed operating picture. Revenue reached EUR 1.93 billion, while adjusted EBITDA was EUR 353 million and the adjusted EBITDA margin improved to 18.3 percent. Reported EBITDA was EUR 316.4 million after EUR 36.6 million in restructuring effects.

Impairments of EUR 136.1 million on long-term assets at Heiligenkreuz and Grimsby contributed to an EBIT loss of EUR 55.1 million. The net loss reached EUR 130.3 million. For the full year, management guides to adjusted EBITDA of EUR 430 million to EUR 460 million.

Investors Await Execution Milestones

Lenzing stock traded at 11.78 euros on Lang & Schwarz at 17:15 CET on Monday, November 9, 2026. The next scheduled financial date is March 18, 2027, when Lenzing plans to publish its 2026 annual results.

Broader conditions remain relevant for Austrian equities; current ATX market developments can influence sentiment across Vienna-listed stocks.

More news and analyses on Lenzing stock.